• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

急性造影剂肾病患者血清肌酐变化轨迹的决定因素

Determinants of serum creatinine trajectory in acute contrast nephropathy.

作者信息

Guitterez Noel V, Diaz Alberto, Timmis Gerald C, O'Neill William W, Stevens Melissa A, Sandberg Keisha R, McCullough Peter A

机构信息

Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan, USA.

出版信息

J Interv Cardiol. 2002 Oct;15(5):349-54. doi: 10.1111/j.1540-8183.2002.tb01067.x.

DOI:10.1111/j.1540-8183.2002.tb01067.x
PMID:12440177
Abstract

The aim of this study was to describe the trajectory of creatinine (Cr) rise and its determinants after exposure to radiocontrast media. Included were 98 subjects who underwent cardiac catheterization and were randomized to forced diuresis with i.v. crystalloid, furosemide, mannitol (if pulmonary capillary wedge pressure was < 20 mmHg), and low dose dopamine versus intravenous crystalloid and matching placebos. Baseline and postcatheterization serum Cr levels were analyzed in a longitudinal fashion, allowing for differences in the time between blood draws, to determine the different critical trajectories of serum Cr. The mean age, baseline serum Cr, and Cr clearance (CrCl) were 69.3 +/- 10.8 years, 2.5 +/- 0.9 mg/dL, and 31.4 +/- 12.1 mL/min, respectively. The clinically driven postprocedural observation time was 5.5 +/- 5.1 days (range 19 hours and one Cr value to 25.7 days and 18 values). The mean maximum Cr was 3.3 +/- 1.4, range 1.7-8.7 mg/dL). Longitudinal models support baseline Cr clearance predictions for the change in Cr at 24 hours, time as the determinant of Cr trajectory, and requisite monitoring. For any given individual, a rise in Cr of < or = 0.5 mg/dL in the first 24 hours after contrast exposure predicted a favorable outcome. Baseline renal function is the major determinant of the rate of rise, height, and duration of Cr trajectory after contrast exposure. Length of observation and frequency of laboratory measures can be anticipated from these models.

摘要

本研究的目的是描述接触放射性造影剂后肌酐(Cr)升高的轨迹及其决定因素。纳入了98例行心导管插入术的受试者,他们被随机分为静脉输注晶体液、速尿、甘露醇(如果肺毛细血管楔压<20 mmHg)和低剂量多巴胺进行强制利尿组与静脉输注晶体液及匹配安慰剂组。以纵向方式分析基线和导管插入术后的血清Cr水平,考虑到采血时间的差异,以确定血清Cr的不同关键轨迹。平均年龄、基线血清Cr和Cr清除率(CrCl)分别为69.3±10.8岁、2.5±0.9 mg/dL和31.4±12.1 mL/min。临床驱动的术后观察时间为5.5±5.1天(范围为19小时和1个Cr值至25.7天和18个值)。平均最大Cr为3.3±1.4,范围为1.7 - 8.7 mg/dL)。纵向模型支持对24小时时Cr变化的基线Cr清除率预测、时间作为Cr轨迹的决定因素以及必要的监测。对于任何给定个体,造影剂暴露后最初24小时内Cr升高≤0.5 mg/dL预示着良好的结果。基线肾功能是造影剂暴露后Cr轨迹上升速率、高度和持续时间的主要决定因素。这些模型可以预测观察时间长度和实验室测量频率。

相似文献

1
Determinants of serum creatinine trajectory in acute contrast nephropathy.急性造影剂肾病患者血清肌酐变化轨迹的决定因素
J Interv Cardiol. 2002 Oct;15(5):349-54. doi: 10.1111/j.1540-8183.2002.tb01067.x.
2
A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.一项针对造影剂肾病高危患者预防措施的前瞻性随机试验:P.R.I.N.C.E. 研究结果。放射性造影剂所致肾病的预防临床评估。
J Am Coll Cardiol. 1999 Feb;33(2):403-11. doi: 10.1016/s0735-1097(98)00574-9.
3
Mannitol, furosemide, and dopamine infusion in postoperative renal failure complicating cardiac surgery.心脏手术后并发肾衰竭时甘露醇、呋塞米及多巴胺的输注治疗
Ann Thorac Surg. 2000 Feb;69(2):501-6. doi: 10.1016/s0003-4975(99)01298-9.
4
Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial.使用甘露醇和呋塞米进行强制等容利尿以预防接受冠状动脉造影的慢性肾脏病患者发生造影剂肾病:一项随机对照试验。
Am J Kidney Dis. 2009 Oct;54(4):602-9. doi: 10.1053/j.ajkd.2009.03.024. Epub 2009 Jun 17.
5
Prevention of postcontrast acute kidney injury after percutaneous transluminal angioplasty by inducing RenalGuard controlled furosemide forced diuresis with matched hydration: study protocol for a randomised controlled trial.通过诱导肾保护控制的呋塞米强制利尿并匹配补液预防经皮腔内血管成形术后造影剂后急性肾损伤:一项随机对照试验的研究方案
BMJ Open. 2018 Oct 4;8(9):e021842. doi: 10.1136/bmjopen-2018-021842.
6
Discordance between serum creatinine and creatinine clearance for identification of ED patients with abdominal pain at risk for contrast-induced nephropathy.血清肌酐与肌酐清除率之间的不一致性用于识别有对比剂肾病风险的腹痛急诊患者。
Am J Emerg Med. 2007 Mar;25(3):268-72. doi: 10.1016/j.ajem.2006.07.011.
7
Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial.速尿联合等渗盐水水化预防对比剂肾病:MYTHOS 研究(对比剂肾病预防中渗透性利尿联合等渗盐水水化与标准水化的比较)
JACC Cardiovasc Interv. 2012 Jan;5(1):90-7. doi: 10.1016/j.jcin.2011.08.017.
8
A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast medium-induced nephropathy: the Dialysis-versus-Diuresis (DVD) Trial.一项比较水化疗法与额外血液透析或N-乙酰半胱氨酸预防造影剂肾病的随机对照试验:透析与利尿(DVD)试验。
Clin Res Cardiol. 2007 Mar;96(3):130-9. doi: 10.1007/s00392-007-0473-4. Epub 2006 Dec 22.
9
Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy.心房利钠肽预防放射性造影剂所致肾病的前瞻性研究。
Am J Kidney Dis. 1998 Apr;31(4):674-80. doi: 10.1053/ajkd.1998.v31.pm9531185.
10
Predictors for contrast media-induced nephropathy and long-term survival: prospectively assessed data from the randomized controlled Dialysis-Versus-Diuresis (DVD) trial.对比剂诱导的肾病及长期生存的预测因素:来自随机对照透析与利尿(DVD)试验的前瞻性评估数据。
Can J Cardiol. 2008 Nov;24(11):845-50. doi: 10.1016/s0828-282x(08)70193-4.

引用本文的文献

1
Sodium-Glucose Cotransporter 2 Inhibitors in Patients Undergoing Coronary Angiography: A Randomized Controlled Trial (BELIEVE Trial).接受冠状动脉造影患者中钠-葡萄糖协同转运蛋白2抑制剂的应用:一项随机对照试验(BELIEVE试验)
Kidney360. 2025 Mar 21;6(8):1317-1327. doi: 10.34067/KID.0000000781.
2
Diuretics for preventing and treating acute kidney injury.用于预防和治疗急性肾损伤的利尿剂
Cochrane Database Syst Rev. 2025 Jan 29;1(1):CD014937. doi: 10.1002/14651858.CD014937.pub2.
3
Effects of iopromide contrast agents on kidney iNOS expression and tubular histopathology alterations.
碘普罗胺造影剂对肾脏诱导型一氧化氮合酶表达及肾小管组织病理学改变的影响。
Narra J. 2024 Dec;4(3):e1227. doi: 10.52225/narra.v4i3.1227. Epub 2024 Nov 21.
4
Long-Term Prognosis of Patients Undergoing Percutaneous Coronary Intervention: The Impact of Serum Creatinine Levels on All-Cause Mortality.经皮冠状动脉介入治疗患者的长期预后:血清肌酐水平对全因死亡率的影响。
Med Sci Monit. 2024 May 29;30:e943063. doi: 10.12659/MSM.943063.
5
Procedural and Technological Innovations Facilitating Ultra-low Contrast Percutaneous Coronary Interventions.促进超低对比度经皮冠状动脉介入治疗的程序和技术创新。
Interv Cardiol. 2023 Mar 29;18:e09. doi: 10.15420/icr.2022.32. eCollection 2023.
6
The relationship between H2FPEF score and contrast induced nephropathy in patients with ST elevation myocardial infarction.ST段抬高型心肌梗死患者中H2FPEF评分与造影剂肾病的关系。
J Cardiovasc Thorac Res. 2022;14(4):240-245. doi: 10.34172/jcvtr.2022.30537. Epub 2022 Dec 24.
7
Subphenotypes in acute kidney injury: a narrative review.急性肾损伤的亚表型:综述。
Crit Care. 2022 Aug 19;26(1):251. doi: 10.1186/s13054-022-04121-x.
8
Association Between Non-Recovered Contrast-Associated Acute Kidney Injury and Poor Prognosis in Patients Undergoing Coronary Angiography.冠状动脉造影患者中未恢复的造影剂相关急性肾损伤与不良预后的关联
Front Cardiovasc Med. 2022 Mar 7;9:823829. doi: 10.3389/fcvm.2022.823829. eCollection 2022.
9
Stenting deferral in primary percutaneous coronary intervention: exploring benefits and suitable interval in heavy thrombus burden.在直接经皮冠状动脉介入治疗中延迟支架置入:探讨在血栓负荷较重情况下的益处及合适的间隔时间。
Egypt Heart J. 2021 Sep 9;73(1):78. doi: 10.1186/s43044-021-00203-3.
10
The global incidence and mortality of contrast-associated acute kidney injury following coronary angiography: a meta-analysis of 1.2 million patients.全球冠状动脉造影后对比剂相关急性肾损伤的发生率和死亡率:一项 120 万患者的荟萃分析。
J Nephrol. 2021 Oct;34(5):1479-1489. doi: 10.1007/s40620-021-01021-1. Epub 2021 Jun 2.